Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623999 | PMC |
| http://dx.doi.org/10.1186/s13045-022-01369-2 | DOI Listing |
Publication Analysis
Top Keywords
correction olverembatinib
4
olverembatinib hqp1351
4
hqp1351 well-tolerated
4
well-tolerated effective
4
effective tyrosine
4
tyrosine kinase
4
kinase inhibitor
4
inhibitor patients
4
patients t315i-mutated
4
t315i-mutated chronic
4
Similar Publications
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
J Hematol Oncol
February 2023
National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, No. 11 South Street of Xizhimen, Xicheng District, Beijing, 100044, China.
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
J Hematol Oncol
October 2022
National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, No. 11 South Street of Xizhimen, Xicheng District, Beijing, 100044, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!